A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.

ABSTRACT:

Background

Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose.

Methods

We used the gene-expression-based radiation-sensitivity index and the linear quadratic model to derive the genomic-adjusted radiation dose (GARD). A high GARD value predicts for high therapeutic effect for radiotherapy; which we postulate would relate to clinical outcome. Using data from the prospective, observational Total Cancer Care (TCC) protocol, we calculated GARD for primary tumours from 20 d

SUBMITTER: Scott JG 

PROVIDER: S-EPMC7771305 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature